Biblio
Acute GVHD: Novel Biological Insights. Biol Blood Marrow Transplant. 2015.
. . Chronic GvHD NIH Consensus Project Biology Task Force: Evolving path to personalized treatment of chronic GvHD. Blood Adv. 2022.
Clinical implications of NUP98::NSD1 fusion at diagnosis in adult FLT3-ITD positive AML. Eur J Haematol. 2023.
Clinical outcomes of allogeneic stem cell transplantation for relapsed or refractory follicular lymphoma: a retrospective analysis by the Fukuoka Blood and Marrow Transplantation Group. Int J Hematol. 2013.
Combination of bortezomib, thalidomide, and dexamethasone (VTD) as a consolidation therapy after autologous stem cell transplantation for symptomatic multiple myeloma in Japanese patients. Int J Hematol. 2014.
Comparative analysis of calcineurin-inhibitor-based methotrexate and mycophenolate mofetil-containing regimens for prevention of Graft-versus-Host Disease after reduced intensity conditioning allogeneic transplantation. Biol Blood Marrow Transplant. 2018.
Composite GRFS and CRFS Outcomes After Adult Alternative Donor HCT. J Clin Oncol. 2020:JCO1900396.
Efficacy and Safety of Aprepitant in Allogeneic Hematopoietic Stem Cell Transplantation. Pharmacotherapy. 2013.
. Hematogones predict better outcome in allogeneic hematopoietic stem cell transplantation irrespective of graft sources. Biol Blood Marrow Transplant. 2018.
Inferior Outcomes with Cyclosporine and Mycophenolate mofetil after Myeloablative Allogeneic Hematopoietic Cell Transplantation. Biol Blood Marrow Transplant. 2019.
Microbiota as Predictor of Mortality in Allogeneic Hematopoietic-Cell Transplantation. N Engl J Med. 2020;382(9):822-834.
Mocravimod, a selective S1PR modulator in allogeneic hematopoietic stem cell transplantation for malignancy. Transplant Cell Ther. 2022.
Novel insights into GVHD and immune reconstitution after allogeneic hematopoietic cell transplantation. Blood Cell Ther. 2023;6(2):42-48.
. Patient-reported long-term quality of life after tisagenlecleucel in relapsed/refractory diffuse large B-cell lymphoma. Blood Adv. 2020;4(4):629-637.